Skip to main content
Premium Trial:

Request an Annual Quote

Oncimmune: Tariq Sethi, Matthew Luttrel, Cléa Rosenfeld

Oncimmune has appointed several members to the firm, including Tariq Sethi as CSO, Matthew Luttrell as chief commercial officer, and Cléa Rosenfeld as its head of investor relations.

Prior to Oncimmune, Sethi held the roles of chief physician scientist, VP of clinical discovery at AstraZeneca, and emeritus professor of respiratory medicine at King's College London. Prior to that, he served as VP of respiratory autoimmunity translational medicine unit at AstraZeneca, as well as professor of respiratory medicine and lung cancer at Edinburgh University. Sethi is also the founder of Galecto Biotech. He will also join Oncimmune's senior leadership team starting Oct. 1.

Before Oncimmune, Luttrell served in senior roles at Takeda. Prior to Takeda, has held roles at Novo Nordisk, Gilead, GlaxoSmithKline, and Shire. He will also join Oncimmune's senior leadership team starting Oct. 1.

Rosenfeld is a senior investor relations and corporate communications professional and was previously head of investor relations at Shire for 11 years.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.